• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非房室模型到房室模型的药代动力学转换的Meta分析——一种多元非线性混合模型

Non-compartment model to compartment model pharmacokinetics transformation meta-analysis--a multivariate nonlinear mixed model.

作者信息

Wang Zhiping, Kim Seongho, Quinney Sara K, Zhou Jihao, Li Lang

机构信息

Division of Biostatistics, Department of Medicine, School of Medicine, Indiana University, Indianapolis, IN 46032, USA.

出版信息

BMC Syst Biol. 2010 May 28;4 Suppl 1(Suppl 1):S8. doi: 10.1186/1752-0509-4-S1-S8.

DOI:10.1186/1752-0509-4-S1-S8
PMID:20522258
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2880414/
Abstract

BACKGROUND

To fulfill the model based drug development, the very first step is usually a model establishment from published literatures. Pharmacokinetics model is the central piece of model based drug development. This paper proposed an important approach to transform published non-compartment model pharmacokinetics (PK) parameters into compartment model PK parameters. This meta-analysis was performed with a multivariate nonlinear mixed model. A conditional first-order linearization approach was developed for statistical estimation and inference.

RESULTS

Using MDZ as an example, we showed that this approach successfully transformed 6 non-compartment model PK parameters from 10 publications into 5 compartment model PK parameters. In simulation studies, we showed that this multivariate nonlinear mixed model had little relative bias (<1%) in estimating compartment model PK parameters if all non-compartment PK parameters were reported in every study. If there missing non-compartment PK parameters existed in some published literatures, the relative bias of compartment model PK parameter was still small (<3%). The 95% coverage probabilities of these PK parameter estimates were above 85%.

CONCLUSIONS

This non-compartment model PK parameter transformation into compartment model meta-analysis approach possesses valid statistical inference. It can be routinely used for model based drug development.

摘要

背景

为实现基于模型的药物研发,第一步通常是根据已发表的文献建立模型。药代动力学模型是基于模型的药物研发的核心部分。本文提出了一种将已发表的非房室模型药代动力学(PK)参数转换为房室模型PK参数的重要方法。本荟萃分析采用多元非线性混合模型进行。开发了一种条件一阶线性化方法用于统计估计和推断。

结果

以MDZ为例,我们表明该方法成功地将10篇文献中的6个非房室模型PK参数转换为5个房室模型PK参数。在模拟研究中,我们表明,如果每项研究都报告了所有非房室PK参数,那么这种多元非线性混合模型在估计房室模型PK参数时相对偏差很小(<1%)。如果某些已发表文献中存在缺失的非房室PK参数,房室模型PK参数的相对偏差仍然很小(<3%)。这些PK参数估计值的95%覆盖概率高于85%。

结论

这种将非房室模型PK参数转换为房室模型的荟萃分析方法具有有效的统计推断。它可常规用于基于模型的药物研发。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0d9/2880414/64309a35b42d/1752-0509-4-S1-S8-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0d9/2880414/64309a35b42d/1752-0509-4-S1-S8-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0d9/2880414/64309a35b42d/1752-0509-4-S1-S8-1.jpg

相似文献

1
Non-compartment model to compartment model pharmacokinetics transformation meta-analysis--a multivariate nonlinear mixed model.非房室模型到房室模型的药代动力学转换的Meta分析——一种多元非线性混合模型
BMC Syst Biol. 2010 May 28;4 Suppl 1(Suppl 1):S8. doi: 10.1186/1752-0509-4-S1-S8.
2
Investigating the contribution of residual unexplained variability components on bias and imprecision of parameter estimates in population pharmacokinetic mixed-effects modeling.在群体药代动力学混合效应模型中,研究残留未解释变异成分对参数估计偏差和不精密度的影响。
J Pharmacokinet Pharmacodyn. 2023 Apr;50(2):123-132. doi: 10.1007/s10928-022-09837-5. Epub 2023 Jan 8.
3
Exploratory population pharmacokinetics (e-PPK) analysis for predicting human PK using exploratory ADME data during early drug discovery research.在早期药物发现研究期间,利用探索性的吸收、分布、代谢和排泄(ADME)数据进行探索性群体药代动力学(e-PPK)分析,以预测人体药代动力学。
Eur J Drug Metab Pharmacokinet. 2009 Apr-Jun;34(2):117-28. doi: 10.1007/BF03191160.
4
Estimation of population pharmacokinetic parameters in the presence of non-compliance.存在不依从性情况下的群体药代动力学参数估计
J Pharmacokinet Pharmacodyn. 2003 Feb;30(1):53-81. doi: 10.1023/a:1023297426153.
5
A fast method for testing covariates in population PK/PD Models.一种用于在群体 PK/PD 模型中检测协变量的快速方法。
AAPS J. 2011 Sep;13(3):464-72. doi: 10.1208/s12248-011-9289-2. Epub 2011 Jul 2.
6
Drug-drug interaction prediction: a Bayesian meta-analysis approach.药物相互作用预测:一种贝叶斯荟萃分析方法。
Stat Med. 2007 Sep 10;26(20):3700-21. doi: 10.1002/sim.2837.
7
A Bayesian meta-analysis on published sample mean and variance pharmacokinetic data with application to drug-drug interaction prediction.一项关于已发表的样本均值和方差药代动力学数据的贝叶斯荟萃分析及其在药物相互作用预测中的应用。
J Biopharm Stat. 2008;18(6):1063-83. doi: 10.1080/10543400802369004.
8
A novel Gibbs maximum a posteriori (GMAP) approach on Bayesian nonlinear mixed-effects population pharmacokinetics (PK) models.一种用于贝叶斯非线性混合效应群体药代动力学(PK)模型的新型吉布斯最大后验概率(GMAP)方法。
J Biopharm Stat. 2009 Jul;19(4):700-20. doi: 10.1080/10543400902964159.
9
Adjusted adaptive Lasso for covariate model-building in nonlinear mixed-effect pharmacokinetic models.用于非线性混合效应药代动力学模型中协变量模型构建的调整自适应套索法
J Pharmacokinet Pharmacodyn. 2017 Feb;44(1):55-66. doi: 10.1007/s10928-017-9504-6. Epub 2017 Jan 31.
10
[Comparative pharmacokinetic analysis based on nonlinear mixed effect model].基于非线性混合效应模型的比较药代动力学分析
Yao Xue Xue Bao. 2011 Apr;46(4):447-53.

引用本文的文献

1
Distribution of enrofloxacin within the bronchoalveolar region of healthy pigs.恩诺沙星在健康猪的支气管肺泡区域内的分布。
J Vet Med Sci. 2023 Mar 1;85(3):296-300. doi: 10.1292/jvms.22-0416. Epub 2023 Jan 17.
2
Distribution of marbofloxacin within the bronchoalveolar region of healthy pigs.马波沙星在健康猪的支气管肺泡区域内的分布。
J Vet Med Sci. 2020 Aug 19;82(8):1080-1083. doi: 10.1292/jvms.20-0239. Epub 2020 Jun 19.
3
Distribution of marbofloxacin in the bronchoalveolar region in healthy calves.健康犊牛支气管肺泡区域中麻保沙星的分布

本文引用的文献

1
A Bayesian meta-analysis on published sample mean and variance pharmacokinetic data with application to drug-drug interaction prediction.一项关于已发表的样本均值和方差药代动力学数据的贝叶斯荟萃分析及其在药物相互作用预测中的应用。
J Biopharm Stat. 2008;18(6):1063-83. doi: 10.1080/10543400802369004.
2
Innovative approaches in drug development.药物研发中的创新方法。
J Biopharm Stat. 2007;17(5):775-89. doi: 10.1080/10543400701513926.
3
Model-based drug development.基于模型的药物研发。
J Vet Med Sci. 2019 May 31;81(5):730-733. doi: 10.1292/jvms.18-0761. Epub 2019 Mar 26.
4
Nonstandard Finite Difference Method Applied to a Linear Pharmacokinetics Model.应用于线性药代动力学模型的非标准有限差分法。
Bioengineering (Basel). 2017 May 4;4(2):40. doi: 10.3390/bioengineering4020040.
5
Determining optimal dosing regimen of oral administration of dicloxacillin using Monte Carlo simulation.使用蒙特卡洛模拟法确定双氯西林口服给药的最佳给药方案。
Drug Des Devel Ther. 2017 Jun 28;11:1951-1956. doi: 10.2147/DDDT.S139632. eCollection 2017.
6
An Algorithm and R Program for Fitting and Simulation of Pharmacokinetic and Pharmacodynamic Data.一种用于药代动力学和药效学数据拟合与模拟的算法及R程序
Eur J Drug Metab Pharmacokinet. 2017 Jun;42(3):499-518. doi: 10.1007/s13318-016-0358-x.
7
Development of a paediatric population pharmacokinetic model for valacyclovir from literature non-compartmental values originating from sparse studies and Bayesian priors: a simulation study.基于稀疏研究得出的文献非房室值和贝叶斯先验构建伐昔洛韦儿科群体药代动力学模型:一项模拟研究
J Pharmacokinet Pharmacodyn. 2015 Jun;42(3):237-50. doi: 10.1007/s10928-015-9412-6. Epub 2015 Mar 29.
8
Text mining for drug-drug interaction.药物相互作用的文本挖掘
Methods Mol Biol. 2014;1159:47-75. doi: 10.1007/978-1-4939-0709-0_4.
9
Exploratory Pharmacokinetics of Geniposide in Rat Model of Cerebral Ischemia Orally Administered with or without Baicalin and/or Berberine.黄芩苷和/或小檗碱对脑缺血大鼠灌胃给药后京尼平苷的探索性药代动力学研究。
Evid Based Complement Alternat Med. 2013;2013:349531. doi: 10.1155/2013/349531. Epub 2013 Dec 3.
10
2K09 and thereafter : the coming era of integrative bioinformatics, systems biology and intelligent computing for functional genomics and personalized medicine research.2K09 及以后:功能基因组学和个性化医学研究中综合生物信息学、系统生物学和智能计算的崭新时代。
BMC Genomics. 2010 Dec 1;11 Suppl 3(Suppl 3):I1. doi: 10.1186/1471-2164-11-S3-I1.
Clin Pharmacol Ther. 2007 Jul;82(1):21-32. doi: 10.1038/sj.clpt.6100235. Epub 2007 May 23.
4
Drug-drug interaction prediction: a Bayesian meta-analysis approach.药物相互作用预测:一种贝叶斯荟萃分析方法。
Stat Med. 2007 Sep 10;26(20):3700-21. doi: 10.1002/sim.2837.
5
Drug development and the FDA's Critical Path Initiative.药物研发与美国食品药品监督管理局的关键路径计划。
Clin Pharmacol Ther. 2007 Jan;81(1):129-33. doi: 10.1038/sj.clpt.6100014.
6
FDA's critical path initiative: a perspective on contributions of biostatistics.美国食品药品监督管理局的关键路径计划:生物统计学贡献之展望
Biom J. 2006 Aug;48(4):559-64. doi: 10.1002/bimj.200510237.
7
Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants.甲氨蝶呤与有机阴离子转运多肽1A2及其基因变体的相互作用。
J Pharmacol Exp Ther. 2006 Aug;318(2):521-9. doi: 10.1124/jpet.106.104364. Epub 2006 May 15.
8
Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.卡马西平诱发的皮肤药物不良反应的遗传易感性。
Pharmacogenet Genomics. 2006 Apr;16(4):297-306. doi: 10.1097/01.fpc.0000199500.46842.4a.
9
Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation.药代动力学/药效学与药物研发阶段:建模与模拟的作用
AAPS J. 2005 Oct 7;7(3):E544-59. doi: 10.1208/aapsj070355.
10
Clinical consequences of cytochrome P450 2C9 polymorphisms.细胞色素P450 2C9基因多态性的临床后果。
Clin Pharmacol Ther. 2005 Jan;77(1):1-16. doi: 10.1016/j.clpt.2004.08.009.